Company Profiles

driven by the PitchBook Platform

Rubicon Genomics

Rubicon Genomics
2000 FOUNDED
M&A STATUS
31-40 EMPLOYEES
M&A LATEST DEAL TYPE
$75M LATEST DEAL AMOUNT
Description

Provider of high quality companion products designed to help in pre-analytical amplification of nucleic acid for research and commercial applications. The company's high quality companion products include Whole Genome Amplification (WGA) kit, Whole Transcriptome Amplification (WTA) and ThruPLEX-FD that comprise of ease of use, robustness and speed to results, enabling physicians to use less sample from a diverse set of sample sources.

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Parent Company
Primary Office
  • 4743 Venture Drive
  • Ann Arbor, MI 48108
  • United States

+1 (734) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Rubicon Genomics’s full profile, request a free trial.

Rubicon Genomics Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Merger/Acquisition 17-Jan-2017 $75M 0000 0000 Completed Generating Revenue
4. Debt - General 15-Jul-2015 000 0000 Completed Generating Revenue
3. Later Stage VC (Series B1) 13-Nov-2007 00.000 0000 000.00 Completed Generating Revenue
2. Convertible Debt 03-Jun-2005 $2.63M $4.12M Completed Startup
1. Early Stage VC (Series B) 01-Feb-2003 $1.49M $1.49M Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Rubicon Genomics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series B1 0,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series B 0,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series A 875,000 $0.010000 $2 $2 1x $2 4.18%
To view this company’s complete Cap Table, request access »

Rubicon Genomics Former Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Arch Development Partners Venture Capital Minority 000 0000 000000 0
BroadOak Capital Partners Venture Capital Minority 000 0000 000000 0
Duchossois Technology Partners Venture Capital Minority 000 0000 000000 0
Michigan Economic Development Government 000 0000 000000 0
Research Corporation Technologies Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »

Rubicon Genomics Executive Team (12)

Name Title Board
Seat
Contact
Info
James Koziarz Ph.D Chariman, President and Chief Executive Officer
Christine Haakenson Ph.D Chief Operating Officer & President
Betsy Long Chief Financial Officer
Jim Babb Ph.D Chief Quality & Compliance Officer
John Langmore Ph.D Co-Founder & Chief Scientific Officer

3 Former Executives

You’re viewing 5 of 12 executives. Get the full list »

Rubicon Genomics Board Members (3)

Name Representing Role Since Contact
Info
Roger Newton Ph.D Self Board Member 000 0000

2 Former Board Members

You’re viewing 1 of 3 board members. Get the full list »